King Wealth Tg Therapeutics, Inc. Transaction History

King Wealth

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$10.23 - $19.34 $98,433 - $186,089	-9,622 Reduced 39.39%	14,803 $223,000
Q4 2022 Feb 09, 2023	BUY	$5.01 - $11.83 $3,131 - $7,393	625 Added 2.63%	24,425 $289,000
Q3 2022 Nov 10, 2022	SELL	$4.57 - $8.4 $22,850 - $42,000	-5,000 Reduced 17.36%	23,800 $141,000
Q3 2021 Nov 12, 2021	SELL	$21.78 - $40.45 $217,800 - $404,500	-10,000 Reduced 25.77%	28,800 $958,000
Q2 2021 Aug 12, 2021	SELL	$32.5 - $48.96 $325,000 - $489,600	-10,000 Reduced 20.49%	38,800 $1.51 Million
Q4 2019 Feb 13, 2020	BUY	$5.1 - $11.2 $51,000 - $112,000	10,000 Added 25.77%	48,800 $542,000
Q2 2019 Aug 13, 2019	SELL	$6.27 - $8.65 $115,994 - $160,025	-18,500 Reduced 32.29%	38,800 $336,000
Q1 2019 May 13, 2019	BUY	$4.02 - $8.04 $87,233 - $174,467	21,700 Added 60.96%	57,300 $461,000
Q4 2018 Feb 14, 2019	BUY	$3.44 - $5.76 $122,464 - $205,056	35,600 New	35,600 $146,000

338

87.6M

2.35M

1.7M

Ticker TGTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 145,274,000
Market Cap $4.23B
Description
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...

Get notified when there are updates to the investment portfolio of King Wealth, based on Form 13F filings with the SEC.

Stay updated on King Wealth with notifications on news.